



HOUSE OF COMMONS

CANADA

Notice Paper

Nos. 1 - 2

Tuesday, February 3, 2004

10:00 a.m.

QUESTIONS

Q-12 — February 2, 2004 — Mr. Cummins (Delta—South Richmond) —

With regard to the use of the risk management of the antimalarial drug mefloquine by Health Canada and the Department of National Defence:

- (a) what antimalarial drugs have been administered to Canadian Forces personnel, giving the deployment and the number of personnel involved for each of the years 2000, 2001, 2002, and 2003;
- (b) is the administration of antimalarial drug always recorded in each soldier's medical record, (if not, indicate each time that its use was not recorded in each soldier's medical record and why);

- (c) has any soldier ever complained that the fact he was taking an antimalarial drug was not recorded in his medical record or the manner in which it was recorded;
- (d) name the adverse events involving Canadian Forces personnel that have been reported by year and by deployment;
- (e) how does the Canadian Forces document anti-malaria prophylaxis;
- (f) how many Canadian Forces members deployed abroad have committed suicide in 2000, 2001, 2002 and 2003 (i) during the mission, (ii) following the mission, (iii) of these how many had been at some time administered mefloquine;
- (g) what adverse events were reported to Health Canada in each of the years 2000, 2001, 2002, and 2003;
- (h) name or describe each adverse event as recorded by Health Canada in each of the years 2000, 2001, 2002, and 2003;
- (i) how many of each of these adverse events were recorded by Health Canada in each of the years 2000, 2001, 2002 and 2003; and
- (j) which of the adverse events reported to Health Canada in each of the years 2000, 2001, 2002, and 2003 involved persons who had been administered the drug while in the Canadian Forces?